Felezonexor
- Generic Name
- Felezonexor
A Trial of a Novel XPO1 Inhibitor in Participants With Advanced Solid Tumors
- First Posted Date
- 2016-01-29
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- Stemline Therapeutics, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT02667873
- Locations
- 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸Florida Cancer Specialist, Sarasota, Florida, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath